Amylin Shareholder Sues Over $7B Sale To Bristol-Myers
A day after announcing its $7 billion sale, California diabetes drugmaker Amylin Pharmaceuticals Inc. and its board of directors were hit with a putative shareholder class action Tuesday in Delaware that...To view the full article, register now.
Already a subscriber? Click here to view full article